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Peroxisome proliferator-activated receptor-γ (PPAR-γ) has currently been considered as molecular target for the treatment of
human metabolic disorders. Experimental data from in vitro cultures, animal models, and clinical trials have shown that PPAR-
γ ligand activation regulates diﬀerentiation and induces cell growth arrest and apoptosis in a variety of cancer types. Tumor
angiogenesis constitutes a multifaceted process implicated in complex downstream signaling pathways that triggers tumor growth,
invasion, and metastasis. In this aspect, accumulating in vitro and in vivo studies have provided extensive evidence that PPAR-γ
ligandscanfunctionasmodulatorsoftheangiogenicsignalingcascade.Inthecurrentreview,thecrucialroleofPPAR-γligandsand
the underlying mechanisms participating in tumor angiogenesis are summarized. Targeting PPAR-γ may prove to be a potential
therapeutic strategy in combined treatments with conventional chemotherapy; however, special attention should be taken as there
is also substantial evidence to support that PPAR-γ ligands can enhance angiogenic phenotype in tumoral cells.
Copyright © 2008 Costas Giaginis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Angiogenesis, the development of new capillaries from pre-
existing microvessels, plays a crucial role in several normal
physiological processes, such as embryonic development,
ovulation, wound healing, as well as tissue and organ
regeneration. Angiogenesis also constitutes a crucial step
in the aetiology of diverse pathological states, including
cancer, diabetic retinopathy, age-related macular degenera-
tion, psoriasis, and rheumatoid arthritis [1, 2]. In the last
few years, the complicated biochemical mechanisms govern-
ing neovessel formation have been well established. These
include the proliferation of endothelial cells (ECs) from
preexisting capillaries, the breakdown and reassembly of the
extracellular matrix (ECM) and the morphogenic process of
endothelial tube formation [2, 3]. Numerous growth factors,
including vascular endothelial growth factor (VEGF) family,
basic ﬁbroblast growth factors (bFGFs), platelet-derived
growth factor (PDGF), hepatocyte growth factor (HGF),
placenta growth factor (PGF), matrix metalloproteinases
(MMPs), ephrin family, angiopoetin-1 (Ang-1), interleukins
(IL-2, -6, -8), as well as various endothelial surface molecules
such CD31, CD34, CD36, CD144, and avb3 integrins, have
been found to control essential steps within angiogenesis
process [1–3]. The generation and release of antiangiogenic
factors, such as interferon (INF) -α,- β,- γ, platelet factor 4
(PF4), and tissue inhibitors of MMPs (TIMPs) contribute
to the coordinated downregulation of the angiogenic process
within physiologic angiogenesis [4].
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily
of ligand-activated transcription factors and include three
diﬀerent isotypes: PPAR-α,P P A R - β/δ, and PPAR-γ [5, 6].
PPAR-γ, the most extensively studied amongst them, func-
tions as ligand-activated transcription factor by binding to
speciﬁc DNA sequences, termed to as peroxisome prolifera-
tor response elements (PPREs), in the promoter of the target
genes only as a heterodimer with the retinoid X receptor2 PPAR Research
(RXR) [7–9]. PPRE has been mainly identiﬁed in the
upstream regulatory sequences of genes related to metabolic
pathways [7–9]. In addition, recent studies have revealed
that PPAR-γ can regulate gene expression independently
of PPRE, either by suppressing growth hormone protein-1
(GHP-1), a transcription factor involved in pituitary speciﬁc
gene expression, or by interfering with the function of
activator protein-1 (AP-1), signal transducer and activator of
transcription-1 (STAT-1) and nuclear factor-κB( N F - κB) [7,
10–12]. In this context, the identiﬁcation of a sumoylation-
dependent pathway by which PPAR-γ represses transcrip-
tionalactivationofinﬂammatoryresponsegeneshasrecently
been reported [13]. This mechanism provides a possible
explanation for how ligand-bound PPAR-γ activation can be
converted from an activator of transcription to a promoter-
speciﬁc repressor of NF-κBt a r g e tg e n e s[ 13].
A wide range of natural and synthetic structurally
diverse compounds has been reported as potent PPAR-γ
ligands. The long chain polyunsaturated fatty acids and
their derivatives, such as 15-deoxy-Δ12,14-prostaglandin J2
(15d-PGJ2), as well as nitrolinoleic acids are known natural
occurring PPAR-γ ligands [14, 15]. Recently, curcumin,
a well-documented anticancer phytochemical component
of turmeric, has been shown to exert anti-inﬂammatory
functions via upregulation of PPAR-γ activation [16]. Thia-
zolidinediones (TZDs) and tyrosine-based derivatives, such
as glitazars (tesaglitazar, farglitazar), constitute the most
well-known synthetic ligands [17, 18], while relatively lower
binding aﬃnity for PPAR-γ has also been reported for
some nonsteroidal anti-inﬂammatory drugs (NSAIDs) [19].
TZDs represent a promising class of oral antidiabetic agents,
some of which are already marketed drugs (pioglitazone-
PGZ and rosiglitazone-RGZ) for the treatment of type II
diabetes mellitus [20]. Interestingly, a wide spectrum of
action for TZDs beyond the treatment of diabetes, including
anti-inﬂammatory and antineoplastic properties, as well as
targeting signaling pathways implicated in atherosclerosis
and osteoporosis has been reported [21–23]. In the last
decade, more than 1000 PPAR-γ ligands belonged to sev-
eral distinct chemical classes have been synthesized and
evaluated for their binding and transactivation to their
receptor. In this aspect, screening drug-like characteristics
in the chemical space of PPAR-γ ligands have currently
been considered as an emerging demand in the aim to
discovermorepotentcompoundswithimprovedabsorption,
distribution, metabolism, excretion/toxicity (ADME/Tox)
properties, avoiding potential toxic side eﬀects, as well as
pharmacokinetic and pharmacodynamic problems [24, 25].
To date, there has been a substantial accumulation
of evidence that PPAR-γ ligands exert regulatory eﬀects
on angiogenesis process related to diverse disease states,
including cancer and diabetes [26–28]. It is also well
documentedthattheydirectlyaﬀecttumorcellsbyinhibiting
cell growth and inducing cell diﬀerentiation and apoptosis
in various cancer types [21, 29, 30]. In view of the fact
that angiogenesis is implicated in tumor development and
metastasis and its inhibition could serve as potent antitumor
side-therapeutic approach, the current review summarizes
the latest knowledge of the role of PPAR-γ ligands in
angiogenesis related to cancer,highlighting in the underlying
mechanisms.
2. ANGIOGENESIS IN CANCER
Tumor angiogenesis constitutes an essential component of
tumorgrowth,invasion,andmetastasisthatdependsonanet
balance of angiogenic and antiangiogenic mediators, which
are secreted by both tumor and host inﬁltrating cells [31].
Currently, it is well established that this dynamic balance
between angiogenic stimulators and inhibitors, controls the
angiogenic signaling cascade governing the transformation
of a tumor from a nonangiogenic to an angiogenic phe-
notype [32]. The acquisition of angiogenic phenotype has
been considered as a rate-limiting step in tumor progression,
which allows the tumor to transform from a small lesion
to a rapidly expanding mass with metastatic potency [33].
On the other hand, human tumors arise in the absence of
angiogenic activity and may exist in a microscopic dormant
state for months to years without neovascularization [34]. In
this context, hypoxia, developed within rapidly proliferating
tissues or as a result of the occlusion of blood vessels,
has been considered as a primary physiological regulator
of the angiogenic switch [35]. The key mediators of this
response are members of the hypoxia-inducible factor (HIF)
family of proteins that function as transcriptional regulators,
stimulating the expression of a multitude of genes important
for oxygen homeostasis [36, 37]. In addition, HIF has
been found to enhance the expression of several angiogenic
mediators, including VEGF-R1, VEGF-R2, Ang-1, Ang-2,
MMP-2, and MMP-9 in malignant tumors [36, 38].
In response to hypoxia, tumor cells turn on the angio-
genic signaling cascade by secreting various potent angio-
genic mediators, such as VEGF, PDGF, bFGFs, angiopoetins,
HGF, ﬁbronectin, and heparanase that in turn activate
endothelial cells of preexisting capillaries to produce MMPs
for the collapse of ECM [39]. Degradation of ECM by MMPs
allowsendothelialcellstomigrateinresponsetochemotactic
growth factors, including VEGF, PDGF, and bFGFs [33, 39].
Members of CXC chemokine family, such as IL-2, -6, -8, and
integrins αvβ3, are also involved in the angiogenic cascade.
It should be noted that in the case of high progressive
tumors, the release of endogenous antiangiogenic factors
are insuﬃcient to counteract the net eﬀect of angiogenic
ones. Thus, the formation of new blood vessel is formed
after attracting accessory cells, mainly pericytes and smooth
muscle cells, producing a new basement membrane and
aﬁ r mE C M[ 39, 40]. The above-mentioned angiogenic
mediators have been joined by others including Notch/Delta,
semaphorin,ephrin,androundabout/slitfamiliesofproteins
[40].Besidesthis,blockageofNF-κBactivityhasbeenshown
to reduce VEGF gene expression in highly malignant tumor
cells, since a binding site for this transcription factor has
been identiﬁed within the VEGF promoter [41]. Each of
the sequential steps within angiogenic cascade could be
considered as a potential single target for the development
of new drug candidates against tumor vasculogenesis.
Currently,numerous therapeutic approaches have been
designed in the aim to control tumor angiogenic cascadeCostas Giaginis et al. 3
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Figure 1: The network of the components implicated in the angiogenesis process in cancer and the impact of PPAR-γ ligands illustrated by
blue color.
by targeting the above-mentioned angiogenic mediators [40,
42]. In this context, more than a few angiogenesis inhibitors
havealreadybeenapprovedforthetreatmentofcancer,while
several compounds are in the late stage of clinical trials. The
main category of the antiangiogenic compounds exerts its
action indirectly either by neutralization of tumor-derived
angiogenic factors or preventing the receptors/signaling
pathways of these growth factors. In this regard, VEGF
isoforms and their tyrosine kinase receptors VEGFRs, as well
as epidermal growth factor (EGF) and its receptor (EGFR)
are currently explored in clinical trials as drug candidates
against cancer [43–45].
With respect to angiogenesis inhibitors, several angio-
static compounds, such as endostatin, thrombospodin-1
(TSP-1), tumstatin, angiostatin, and 16-kDa N-terminal
fragment of human prolactin (16K hPRL) have been
reported to directly and selectively suppress endothelial cell
migration inducing EC apoptosis and cell cycle arrest within
tumor neovascularization [46, 47]. It should be mentioned
that most of these angiostatic compounds are also natu-
rally occurring molecules that compensate with angiogenic
factors in order to control angiogenic cascade in normal
physiologic conditions. In addition, targeting MMPs by such
agents has been reported, underlining the importance of
ECM remodeling during angiogenesis process. Activation of
NF-κB may also be a possible mechanism of such angiostatic
agents to induce EC apoptosis and to improve immune
response within angiogenesis process [46, 47].
3. INHIBITION OF ANGIOGENESIS BY
PPAR-γ LIGANDS
PPAR-γ ligands can regulate tumor angiogenesis via direct
eﬀects on ECs proliferation and migration and/or through
indirect mode of action by aﬀecting the counterbalance




and PPAR-γ ligands are well established to exert direct eﬀects
on them [48, 49]. PPAR-γ activation by either naturally
occurring or synthetic ligands resulted in potent inhibition
of growth factor-induced diﬀerentiation and proliferation
in human umbilical vein endothelial cells (HUVECs) and
choroidal endothelial cells (CECs) [48, 49]. In this regard,
PPAR-γ dependent mode of action has been shown to stimu-
late caspase-mediated ECs apoptosis [50]. Importantly, RGZ
levels able to inhibit ECs proliferation are readily achieved
in patients undergoing standard antidiabetic RGZ treatment
[51]. Moreover, both RGZ and PGZ, at relative pharma-
cological concentrations, resulted in a strong prevention of
VEGF-induced tube formation and ECs migration [52, 53].
Mechanistically, it has been supported that angiogenesis
inhibition by RGZ in HUVECs involves a proapoptotic
mechanism which includes the implication of the PPAR-γ-
mediated NO production and the maxi-K channel activation
[54]. Maxi-K channels, essential mediators of vascular
remodeling and angiogenesis, are synergically regulated by
various intracellular second messengers including NO [54].
Hence, a possible proapoptotic mechanism for the PPAR-γ-
mediated NO production has been suggested [55]. Recently,
pigment epithelium-derived factor (PEDF), a potent antian-
giogenic glycoprotein, has been shown to stimulate HUVECs
apoptosisthroughsequentialinductionintheexpressionand
transcriptional activity of PPAR-γ. PEDF upregulated p53
expression via PPAR-γ, supporting evidence that p53 may be
a major target in PPAR-γ mediated ECs apoptosis [56].
PPAR-γ has also been reported to be expressed in tumor
ECs, presenting a relative overexpression in tumor-induced
endothelial sprouts compared to normal endothelium. In
this case, endothelial and tumoral cells have been shown to
display inhibition even at low TZDs doses [57]. Importantly,
TZDs inhibited tumor cell invasion across blood vessel
endothelium. In fact, RGZ at concentrations close to the
rangeofitsbindingaﬃnityforPPAR-γ [8]exertedinhibitory
eﬀects on tumor angiogenesis in malignant cell lines and
in immunodeﬁcient mice with transplanted tumors [57]. In
this regard, it should be mentioned that RGZ concentrations
of 5μM and higher led to the phosphorylation of eIF-
2α in HUVECs, supporting evidence that the inhibition of
ECs proliferation could also be mediated through a PPAR-γ
independent pathway. However, at even lower concentration4 PPAR Research
Table 1: Eﬀects of PPAR-γ ligands on tumor angiogenesis.
PPAR-γ ligands Type of cells/organisms Eﬀects Ref.
RGZ
In vitro
Glioblastoma U87 VEGF↓ [57]
Lewis lung carcinoma VEGF↓ [57]
Pancreatic tumor AsPC-1 cells tPA↓ [58]
Human breast cancer cell line MDA-MB- TIMP-1↑ [59]
231 gelatinases↓
Transformed human endometrial cells VEGF↓ [60]
(transiently transfected Ishikawa cells)
Human anaplastic thyroid carcinoma cells invasive potential↓ [61]
MSA, IAA, ROA, K119, KOA-2
In vivo
Chick chorioallantoic membrane Choroidal [57]
neovascularization↓
C57/BL6 xenografted with 253J B-v Neovascularization↓ [62]
bladder tumor cells EC apoptosis↑
TGZ
In vitro
Human non small cell lung ELR+CXC [63]
cancer cells A459 chemokines↓
In vivo
C57/BL6 xenografted with 253J B-v Neovascularization↓ [62]
bladder tumor cells EC apoptosis↑
CGZ
In vitro
Human non-small-cell lung carcinoma PGE2, COX-2↓ [64]
A427 and A549 cell
Human ovarian cancer cells OVCAR-2, VEGF, PGE2↓ [65]
DISS
In vivo




Renal cell carcinoma cells SMKT-R-1, -2, VEGF, bFGF↓ [66]
-3, -4
Human non small cell lung ELR+CXC [63]
cancer cells A459 chemokines↓
Human anaplastic thyroid carcinoma cells invasive potential↓ [61]
MSA, IAA, ROA, K119 and KOA-2
15d-PGJ2
In vitro
Renal cell carcinoma SMKT-R-1, -2, -3, -4 VEGF, bFGF↓ [66]
Human gastric cancer Ang-1↓ [67]
cells MKN45
Human PC-3 cells VEGF↑ [68]
Human 5637 urinary bladder cells VEGF↑ [68]
Human breast MCF-7 cells VEGF↑ [69]
Human anaplastic thyroid carcinoma cells invasive potential↓ [61]
MSA, IAA, ROA, K119, KOA-2
Human pancreatic cancer cells BxPC-3 MMP-2, -9↓ [70]
Transformed human endometrial cells VEGF↓ [60]
(transiently transfected Ishikawa cells)
In vivo
C57/BL6 xenografted with 253J B-v Neovascularization↓ [62]
bladder tumor cells EC apoptosis↑Costas Giaginis et al. 5
Table 1: Continued.
PPAR-γ ligands Type of cells/organisms Eﬀects Ref.
RS5444
In vitro
Human anaplastic thyroid carcinoma cells CD31↓ [71]
DRO90-1, ARO81
In vivo




Human anaplastic thyroid carcinoma cells Invasive potential↓ [61]
MSA, IAA, ROA, K119, KOA-2
Nimesulide
In vitro
Human pancreatic cancer cells BxPC-3 VEGF↑ [72]
and MIA PaCa-2
range (0.1–1μM), at which PPAR-γ is activated, RGZ was
capable of exerting even stronger antiproliferative eﬀects on
ECs in vitro [57]. In this context, the concentration range of
PPAR-γ ligands should be taken into careful consideration,
because over a concentration limit, which may be varied
amongst the diﬀerent types of cells, in vitro, as well as
amongst diﬀerent species, in vivo, receptor-independent
actions could be elicited. Such PPAR-γ mode of action has
recently been reviewed by Feinstein et al., who suggested
an alternative mitochondrial target for TZDs, termed as
mitoNEET [12]. To this point, it should be noted that higher
doses of RGZ were less eﬀective in inhibiting angiogenesis
and hence lung metastasis than lower doses that are actually
comparable to the serum levels of RGZ in diabetic patients
[27, 51]. Overall, although PPAR-γ ligands can also induce
EC apoptosis as mentioned in the previous paragraph, it is
unlikely that they do this under physiological conditions as
this may result in a severe thrombosis. Thus, it should be
emphasized the fact PPAR-γ ligands may target better EC
proliferation as shown by Panigrahy et al. [27] and Freed
et al. [51].
Orthotopic implantation of H2122 nonsmall cell lung
adenocarcinoma cells overexpressing PPAR-γ into the lungs
of nude mice attenuated tumor growth and metastasis by
selective inhibition of invasive metastasis, and activation
of pathways that promote a more diﬀerentiated epithelial
phenotype [73]. This evidence deserves special attention
since both angiogenesis and invasion are crucial for the
formation of metastasis and the recurrence of tumors.
Moreover, reintroduction of exogenous TSP1 or its peptide
derivative ABT510 can reverse the angiogenic switch, and
thus blocking tumor expansion. TSP-1 is a well-known
potent angiogenesis inhibitor that targets ECs for apoptosis
through signaling cascade at its receptor CD36. In tumor
xenografts, TGZ, RGZ, and 15d-PGJ2 coupled to ABT510
suppressed angiogenesis and induced ECs apoptosis in a
CD36 dependent manner [62]. In this context, 15d-PGJ2
treatment upregulated CD36 surface expression in human
monocytic cell line THP-1 by enhancement of CD36 gene
transcription [74]. Thus, PPAR-γ could be considered as a
critical regulator of CD36 expression, as both natural and
synthetic PPAR-γ ligands are capable of increasing CD36
expression [75].
Receptor-mediated eﬀects for PPAR-γ ligands in inhibit-
ing angiogenesis through direct mode of action on endothe-
lium seem to be dominated [28, 57]. In this regard, PPAR-
γ knockout mice embryos died on day 10 of life because
of interference with the terminal diﬀerentiation pattern of
trophoblasts, as well as the loss of vascular development
in the placenta [76, 77]. It has also been suggested that
PPAR-binding protein (PBP), a coactivator of PPAR-γ,m a y
function as a negative modulator of ECs proliferation [77].
Such genetic data provides additional evidence that PPAR-γ
functions as modulator of angiogenesis; however, receptor-
independent action should not be excluded. In this aspect,
Artwohl et al. showed PPAR-γ-independent antiproliferative
eﬀects on HUVECs associated with lactate release, possibly
due to inhibition of mitochondrial function [78].
3.2. Indirecteffectsonthenetbalancebetween
angiogenicandantiangiogenicfactors
Beyond the direct mode of action on the endothelium,
PPAR-γ ligands have been reported to downregulate angio-
genesis process via indirect mechanisms by modulating the
levels of the endogenous angiogenesis mediators (Figure 1,
Table 1). In this context, VEGF/VEGFR signaling pathway
seems to be a key target for PPAR-γ ligands in inhibiting
angiogenesis. Xin et al. provided the ﬁrst evidence that 15d-
PGJ2 reduced VEGFRs m-RNA levels in HUVECs [48].
It has also been supported that PPAR-γ ligands may have
bifunctional properties in KDR gene expression that involve
the enhancement of Sp1-DNA binding in absence of ligand
by PPAR-γ itself and the suppression of Sp1-DNA-binding
in presence of PPAR-γ ligands [79]. Moreover, PPAR-γ
activation has been shown to downregulate leptin and tumor
necrosis factor (TNF-α), two well-known angiogenesis-
inducing factors [80, 81]. In fact,PPAR-γ activation byTZDs
attenuated leptin gene expression both in vivo and in vitro
[82, 83] and blocked leptin-induced ECs migration through
inhibition of Akt and eNOS signaling [84]. This evidence
suggests that endothelial phosphatase and tensin homologue6 PPAR Research
mutated on chromosome ten (PTEN), a negative regulator
of PI3K → Akt signaling, may play a crucial role in the ECs
antimigratory actions of TZDs [84].
Tumor-associated angiogenesis has been reported to
be indirectly suppressed by blocking the expression of
angiogenic stimulators in response to PPAR-γ ligand acti-
vation. In this regard, PPAR-γ activation by TGZ or PGZ
diminished the production of the angiogenic ELR+CXC
chemokines IL-8 (CXCL8), ENA-78 (CXCL5), and Gro-
α (CXCL1) in human non-small-cell lung cancer cell line
A459 [63]. This eﬀect was ascribed to the negative mod-
ulation of NF-κBa c t i v a t i o n[ 63]. In addition, CGZ was
foundtodecreasePGE2 productionthroughdownregulation
of cyclooxygenase-2 (COX-2) expression in human non-
small-cell lung carcinoma A427 and A549 cell lines [64].
Interestingly, utilization of a dominant negative PPAR-γ
constructrevealedthattheeﬀectofCGZonbothCOX-2and
PGE2 was mediated through PPAR-γ independent pathways
[64]. Another study demonstrated that 15d-PGJ2 attenuated
the expression of Ang-1 and hence the angiogenic process
through the angiopoietin-Tie2 system in the gastric cancer
cell line MKN45 [67]. Ang-1 is involved in the regulation
of maturation and stabilization of the vascular wall, and
thus it might be a potential target for inhibiting tumor
angiogenesis. Moreover, in a model of human anaplastic
thyroid carcinoma, RS5444, a novel high-aﬃnity PPAR-γ
agonist exerted potent antiangiogenic action, in vivo, by
decreasing CD31, a speciﬁc molecular marker of blood
vessels [71]. In this regard, PPAR-γ ligand treatment (TZDs,
15d-PGJ2, and RS1303) dose-dependently suppressed cell
proliferation by inducing apoptosis instead of diﬀerentiation
in ﬁve human anaplastic carcinoma cell lines (MSA, IAA,
ROA, K119, and KOA-2) [61]. Recently, CGZ has also
been shown to produce antitumor eﬀects against ovarian
cancer, in vitro and in vivo, in conjunction with reduced
angiogenesis and induction of apoptosis [65]. In this case,
CGZ induced antitumor eﬀects were comparable to that of
cisplatinandwereascribedtoinhibitionofVEGFproduction
in relation to PGE2 reduction, an endogenous stimulator of
angiogenesis and invasiveness [65]. PPAR-γ ligands have also
been shown to repress VEGF gene expression via a PPAR-
γ-responsive element (PPRE) in the VEGF gene promoter
in both primary and transformed human endometrial cell
cultures [60]. This study provided substantial evidence
that PPAR-γ ligands may be exploited pharmacologically
to inhibit pathological vascularization in complications of
pregnancy,endometriosis,andendometrialadenocarcinoma
[60].
As mentioned in Section 3.1, RGZ suppressed tumor
angiogenesis by direct mode of action in endothelium; how-
ever, indirect antiangiogenic eﬀects have also been reported
[57]. More to thepoint, RGZ, atlow doses, in vitro, inhibited
bovine capillary ECs and reduced VEGF production by
tumor cells [57]. RGZ also suppressed angiogenesis in the
chick chorioallantoic membrane, in the avascular cornea,
i nv i v o ,a sw e l la si nav a r i e t yo fp r i m a r yt u m o r s ,s u c h
as glioblastoma U87 and Lewis lung carcinoma cells, in
vitro [57]. Likewise, both PGZ and 15d-PGJ2 have been
shown to inhibit, dose- and time-dependently, VEGF and
bFGF secretion in human renal cell carcinoma cells [66].
Importantly,antiangiogenic eﬀectswereobservedatthedose
of 5μM PGZ, a level that is also obtained in diabetic patients
after standard PGZ treatment [66]. On the other hand,
there is nonavailable data so far concerning the eﬀect of
PPAR-γ ligand treatment on the expression and/or secretion
of antiangiogenic mediators. In this regard, future studies
focused on the impact of PPAR-γ ligands in mediators, such
as endostatin, TSP-1, tumstatin, angiostatin, and 16K hPRL
are strongly recommended.
Angiogenesis constitutes a crucial step for tumor inva-
sion and formation of metastasis. In this aspect, PPAR-γ
ligand treatment attenuated the invasiveness of pancreatic
tumor cells, reducing MMP-2 and -9 protein levels and
activity [70]. Moreover, the secretion of the invasive factor
tissue plasminogen activator (tPA) was decreased by RGZ
treatment in pancreatic tumor AsPC-1 cells through recep-
tor mediated mechanisms [58]. Treatment of the highly
aggressive human breast cancer cell line MDA-MB-231
with synthetic and natural PPAR-γ ligands, at noncytotoxic
concentrations, also resulted in a signiﬁcant inhibition of the
invasive capacity [59]. In fact, TIMP-1 was upregulated by
PPAR-γ ligand treatment, while the gelatinolytic activities
of gelatinases in the conditioned media were decreased
[59]. Moreover, PPAR-γ ligands downregulated the invasive
potential of anaplastic thyroid carcinoma cells, and this
eﬀect was prominent in 3 cell lines, which exhibited higher
expression level of the PPAR-γ gene or protein [61].
Clinical evidence from a pilot study enrolled 6 patients
with angiosarcoma and hemangioendothelioma, revealed
that the angiostatic triple combination of PGZ, rofecoxib,
and metronomic trofosfamide exhibited high eﬃcacy in the
palliative care of patients [85]. Until this study, antian-
giogenic drugs such PGZ and rofecoxib had not been
considered for the treatment of human angiosarcoma. In
support of this view, a case report study has demonstrated
that this novel antiangiogenic therapy was eﬀective in a
patient with endemic Kaposi sarcoma and led to partial
remission that was stable for 18 months without signiﬁcant
side eﬀects [86]. Hence, targeting PPAR-γ may prove to
be a potential therapeutic strategy in combined treatments
with conventional chemotherapy for patients with vascular
disorders [87].
4. INDUCTION OF ANGIOGENESIS BY
PPAR-γ LIGANDS
The most comprehensive data so far render PPAR-γ ligands
as potent inhibitors of angiogenesis; however, there are
several lines of evidence to support that PPAR-γ ligand
activation can also trigger angiogenic cascade (Table 1). In
fact, increased VEGF mRNA levels and induction of angio-
genesis in response to PPAR-γ ligands treatment have been
reported both in vitro and in vivo [88–91]. Interestingly,
TZDs have been considered as potential pharmacological
agents for angiogenesis induction in the treatment of
ischemic artery disease [89]. Recent clinical evidence has
also demonstrated that RGZ treatment improved endothelial
progenitor cell (EPC) number and migratory activity inCostas Giaginis et al. 7
diabetic patients [92, 93]. In addition, PGZ treatment was
found to improve endothelial function by increasing the
number and the migratory capacity of EPCs in animal and
human studies [94, 95]. Another study has revealed that
eNOS upregulation induced by RGZ may be the dominant
mechanismthroughwhichRGZenhancedangiogenesis[91].
However, Gensh et al. did not observe upregulation of
vascular eNOS mRNA expression or setback of the PGZ-
induced increase of EPCs in the presence of 1-NAME, a
NOS inhibitor [94]. These authors suggested that TZDs may
regulate EPCs by a mechanism independent of eNOS [94];
however, further studies based on pharmacologic blocking
or knockout modeling of eNOS are strongly recommended
in order for precise conclusion to be drawn. Importantly,
taking into account the discrepancy in literature, Gensh
et al. assumed that TZDs may play a double-edged role
in angiogenesis signaling by promoting the number and
migration of EPCs at lower tissue concentrations obtained
by systematic treatment, whereas the antiangiogenic eﬀects
are elicited at higher local concentrations [94]. This major
remark has also been reported in the case of breast cancer
cells where low concentration of PPAR-γ ligands increase
cell proliferation in contrast to the higher concentrations
t h a ts u p p r e s sc e l lg r o w t h[ 96]. The urgent demand to deﬁne
and monitor the dosage of PPAR-γ ligands in clinical trials
for cancer therapy is thoroughly discussed by Panigrahy
et al. [27]. In this aspect, special attention deserves the fact
that atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitor, and PGZ increased
myocardial 15d-PGJ2 levels in the rat myocardium and
HUVECs [97]. 15d-PGJ2 was produced mainly via COX-
2a n da c t i v a t e dP P A R - γ. Interestingly, it was supported
that PPAR-γ activation was exclusively mediated by 15d-
PGJ2 in the case of atorvastatin, whereas PGZ activated
directly PPAR-γ or indirectly via 15d-PGJ2 [97]. Thus, these
recent ﬁndings raise the question whether the ﬁnal eﬀect
of PPAR-γ ligands is completely ascribed to the dose of
PPAR-γ ligand treatment or in addition to the induction
of endogenous PPAR-γ activators, such as 15d-PGJ2. It
should also be taken into account the fact that endogenous
nitrated fatty acids that comprise a class of nitric oxide-
derived, PPAR-γ dependent and cell signaling mediators
can modulate systematic inﬂammatory responses within
physiological concentration ranges [98].
There is also substantial evidence, which suggests that
PPAR-γ ligands stimulate tumor angiogenesis. In this con-
text, 15d-PGJ2 treatment was found to dose-dependently
increase the VEGF mRNA expression in both human
androgen-independentPC-3prostateand5637urinaryblad-
der carcinoma cells [68]. In addition, 15d-PGJ2 resulted in
upregulation of VEGF expression through the induction of
heme oxygenase (OH)-1 ERK1/2 phosphorylation in human
breast cancer MCF-7 cells, thus contributing to increased
angiogenesis in this type of tumor cells [69]. Nimesulide,
a selective COX-2 inhibitor, although at relatively high
concentrations, enhanced VEGF secretion from pancreatic
cancer cells in vitro, as well as from both COX-2-positive
and COX-2-negative pancreatic tumors through PPAR-γ
activation [72]. Importantly, in the case of COX-2-negative
pancreatic tumors, nimesulide-stimulated VEGF production
was considerably associated with enhanced angiogenesis
and tumor growth [72]. Besides this, VEGF was diﬀer-
entially increased, according to the diﬀerentiation state of
the cells, by the three PPAR isotypes, -α,- β/δ,a n d- γ,
in two diﬀerent human urinary bladder cancer cell lines,
RT4 and T24, derived from grade-I and grade-III tumors,
respectively [99]. The PPAR ligand-induced VEGF expres-
sion seemed to be PPAR-speciﬁc and involved an indirect
mechanism requiring an intermediary regulatory protein
through the MAP (ERK1/2) kinase pathway, probably by
a modulation of the phosphorylation state of PPARs [99].
Immunohistochemical analysis in human bladder tumor
specimens also revealed statistically signiﬁcant associations
between PPAR-γ and several angiogenic factors, such as
VEGF, bFGF, platelet-derived endothelial cell growth factor
(PDECGF), and EGFR in respect to the incidence of tumor
recurrence or progression [100]. On the other hand, no
statistically signiﬁcant diﬀerences were observed between
PPAR-γ immunoreactivity and angiogenesis parameters in
skin cancer,whereasthe microvessel density wassigniﬁcantly
higher in actin keratosis and squamous cell carcinoma that
expressed PPAR-β/δ [101]. These clinical data on PPAR-γ-
induced signaling implicated in the expression of crucial
angiogenic factors in human neoplasia may unfold the
developmentofnewtherapeuticapproachesinthosetypesof
cancer in which excessive angiogenesis represents a negative
prognostic factor.
5. THE IMPACT OF PPAR-γ LIGANDS IN
HYPOXIA-ASSOCIATED SIGNALING PATHWAYS
As hypoxia is a key regulator of the angiogenic switch,
hypoxia-inducedangiogenesisisgaininggraduallyincreasing
interest as a potential target for cancer therapy. In human
bladder tumors and cell lines, several components of the
hypoxia response pathway, including HIF-1α and HIF-
2α have been considered as important cofactors of the
regulation of VEGF [102]. Recent ﬁndings have revealed
that PPAR-γ can modulate arterial remodeling associated
with hypoxic hypertension [103]. In fact, RGZ was found
to attenuate and reverse pulmonary arterial remodeling and
neomuscularization in rats subjected to chronic hypoxia
[104]. Decreased pulmonary arterial (PA) remodeling in
RGZ-treated animals was associated with decreased smooth
muscle cell proliferation, decreased collagen and elastin
deposition, and increased matrix MMP-2 activity in the PA
wall [104]. In this aspect, PPAR-γ mRNA levels were found
signiﬁcantly lower in human adhesion ﬁbroblasts compared
to normal ones in response to hypoxia [105]. Moreover,
hypoxia has demonstrated to reduce the mRNA levels of
PPAR-γ protein in human proximal renal tubular epithelial
cells (HPTECs). However, knockout of HIF-1α with its
dominant negative form did not block the hypoxia-induced
r e d u c t i o ni nP P A R - γ expression [106]. In this regard, sub-
stantial evidence has revealed that 15d-PGJ2 can modulate
the activities of several transcriptional factors, such as NF-
κB and AP-1, including also HIF-1 [107]. The regulation of
the aforementioned redox-sensitive transcription factors by8 PPAR Research
15d-PGJ2 was not necessarily mediated via PPAR-γ activa-
tion, but rather involves covalent modiﬁcation or oxidation
of their critical cysteine residues acting as a redox sensor
[107]. Overall, targeting hypoxia-induced angiogenesis by
PPAR-γ ligands may prove to be a promising therapy for
the treatment of cancer; however, the precise mechanisms
involved in hypoxia-induced angiogenesis process remain to
be clariﬁed.
6. CONCLUSION
At the present, there is quite a lot of evidence to support that
PPAR-γ may be considered as therapeutic target for diverse
disease states in which excessive angiogenesis is implicated,
including cancer. The most comprehensive data so far
have revealed that PPAR-γ ligands are capable of inhibiting
angiogenesis implicated in tumor malignant transformation
and expansion. Targeting ECs proliferation and migration
seems to be a dominant eﬀect of PPAR-γ ligands on tumor
angiogenesis. Indirect mechanisms that involve the coun-
terbalance between a multitude of endogenous angiogenic
and antiangiogenic factors further account for the inhibitory
eﬀects of PPAR-γ ligands on tumor angiogenesis. According
to these data, PPAR-γ ligands may unfold new perspectives
in clinical use against primary tumor growth and metastasis,
since tumors that exhibit multidrug resistance are eﬀectively
targeted by antiangiogenic chemotherapy. Such perspectives
could be clinically relevant, as PGZ and RGZ are orally
administered FDA-approved drugs, already been used by
millionpatientsundergoingstandardantidiabetictreatment.
On the other hand, there are several lines of evidence
that PPAR-γ ligands can also enhance tumor angiogenesis
progressionundercertainconditions.Thiscontroversycould
be attributed to the pleiotropic action of PPAR-γ ligands,
possibly via cofactors, either coactivators or corepressors.
Such discrepancies may also be ascribed either to diﬀerences
in time and dose of PPAR-γ ligand treatment, or to
diﬀerences among the various organisms and types of cells
that have been studied. It should be taken into account
that angiogenesis is a multifaceted process that involves a
wide range of mediators capable of inducing or suppressing
angiogenesis in addition to the degree of tissue hypoxia.
Consequently, the ﬁnal outcome is diﬃcult to be assessed
accuratelyanddependssigniﬁcantlyonexperimentalmodels
and/or treatment conditions. Moreover, each type of cancer
in humans presents individual and distinct vascular pattern
on the microenvironment in which it is located. Thus, it
should be taken into careful consideration the type of cancer
being treated when deciding an appropriate therapeutic
strategy.
In this aspect, the use of diﬀerent cancer models, in
vitro and in vivo, are strongly recommended to further
deﬁne the molecular interactions amongst PPAR-γ, angio-
genic/antiangiogenicfactors,andtumorprogressionmarkers
withinthedistinctcancertypes.Futureresearcheﬀortshould
also be orientated to the clinical evaluation of PPAR-γ
expression in aggressive tumor cancers in which various
angiogenic/antiangiogenic factors exhibit high prognostic
value. Such studies could delineate the potential of PPAR-γ
ligands in future anticancer therapeutic strategies, either
alone or combined with conventional chemotherapy.
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